$14.91
0.47%
NYSE, Nov 19, 09:30 am EST. Market open.
ISIN
US2561352038
Symbol
RDY

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock price

$14.98
+1.90 14.53% 1M
+1.38 10.15% 6M
+0.94 6.70% YTD
+0.96 6.85% 1Y
+1.48 10.96% 3Y
+2.42 19.23% 5Y
+5.72 61.77% 10Y
+11.80 370.77% 20Y
NYSE, Closing price Wed, Nov 18 2026
+0.19 1.28%
Compare with Peer Group
ISIN
US2561352038
Symbol
RDY
Industry

Is Dr. Reddy's Laboratories Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$12.4b
Enterprise Value
$12.3b
Net debt
positive
Cash
$856.2m
Shares outstanding
833.1m
Valuation
P/E
41.6
P/S | estimate
3.5 | 3.2
EV/Sales | estimate
3.5 | 3.2
EV/FCF | ex SBC
242.3 | -
P/B
3.0
Dividends
DPS
$0.08
Yield 1Y | 5Y
0.6% | 0.7%
Growth 1Y | 5Y
-8.8% | 4.4%
Payout 1Y | 3Y
16.9% | 14.2%
Increased
0 Years
Financials
Revenue | estimate
$3.5b | $3.8b
EBITDA
$552.0m
EBIT
$322.9m
Net Income
$299.6m
Free Cash Flow | ex SBC
$50.7m | -
Growth
Revenue | estimate
-3.5% | 5.9%
EBITDA
-40.3%
EBIT
-55.2%
Net Income
-51.5%
Free Cash Flow
-74.3%
Margin
Gross
61.1%
EBITDA
15.6%
EBIT
9.1%
Net
8.5%
Free Cash Flow | ex SBC
1.4% | -
Financial Health
Equity Ratio
65.2%
Return on Equity
11.1%
ROCE
7.2%
ROIC
5.9%
Debt/Equity
0.2
More
EPS
$0.4
FCF per Share
$0.1
Short interest
3.7%
Employees
28k
Rev per Employee
$130.0k

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

42 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

26x Buy
62%
9x Hold
21%
7x Sell
17%

Analyst Opinions

42 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

Buy
62%
Hold
21%
Sell
17%

Dr. Reddy's Laboratories Ltd. Sponsored ADR Events

Past Events
OCT
23
Q2 2027 Earnings Call
27 days ago
JUL
22
Q1 2027 Earnings Call
4 months ago
JUL
9
Special Call - Dr. Reddy's Laboratories Limited
4 months ago
MAY
12
Q4 2026 Earnings Call
6 months ago
JAN
21
Q3 2026 Earnings Call
10 months ago
OCT
24
Q2 2026 Earnings Call
about one year ago

Financial data from Dr. Reddy's Laboratories Ltd. Sponsored ADR

Sep '26
+/-
%
3,542 3,542
4% 4%
100%
- Direct Costs 1,376 1,376
13% 13%
39%
2,165 2,165
12% 12%
61%
- Selling and Administrative Expenses 674 674
20% 20%
19%
- Research and Development Expense - -
-
-
552 552
40% 40%
16%
- Depreciation and Amortization 229 229
12% 12%
6%
EBIT (Operating Income) EBIT 323 323
55% 55%
9%
Net Profit 300 300
51% 51%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Dr. Reddy's Laboratories Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News

Positive
Reuters
●
2 months ago
Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.
Neutral
Business Wire
●
4 months ago
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.
More Dr. Reddy's Laboratories Ltd. Sponsored ADR News

Company Profile

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Head office India
CEO Mr. Israeli
Employees 27,527
Founded 1984
Website www.drreddys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today